Clinical Trial Update: Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating oral glutamine to prevent oxaliplatin-induced neurotoxicity in colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Glutamine (glutamine)

Snippet

Sponsor: Sanofi | Conditions: Colorectal Neoplasms | Phase 3 | Status: COMPLETED